{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:39:15Z","timestamp":1778395155616,"version":"3.51.4"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SCHI510\/12-1"],"award-info":[{"award-number":["SCHI510\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:p>The efficacy of targeting the MAPK signaling pathway in patients with melanoma is limited by the rapid development of resistance mechanisms that result in disease relapse. In this article, we focus on targeting the DNA repair pathway as an antimelanoma therapy, especially in MAPK inhibitor resistant melanoma cells using PARP inhibitors. We found that MAPK inhibitor resistant melanoma cells are particularly sensitive to PARP inhibitor treatment due to a lower basal expression of the DNA damage sensor ataxia-telangiectasia mutated (ATM). As a consequence, MAPK inhibitor resistant melanoma cells have decreased homologous recombination repair activity leading to a reduced repair of double-strand breaks caused by the PARP inhibitors. We validated the clinical relevance of our findings by ATM expression analysis in biopsies from patients with melanoma before and after development of resistance to MAPK inhibitors. Furthermore, we show that inhibition of the MAPK pathway induces a homologous recombination repair deficient phenotype in melanoma cells irrespective of their MAPK inhibitor sensitivity status. MAPK inhibition results in a synthetic lethal interaction of a combinatorial treatment with PARP inhibitors, which significantly reduces melanoma cell growth in vitro and in vivo. In conclusion, this study shows that PARP inhibitor treatment is a valuable therapy option for patients with melanoma, either as a single treatment or as a combination with MAPK inhibitors depending on ATM expression.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We show that MAPK inhibitor resistant melanoma cells exhibit low ATM expression increasing their sensitivity toward PARP inhibitors and that a combination of MAPK\/PARP inhibitors act synthetically lethal in melanoma cells. Our study shows that PARP inhibitor treatment is a valuable therapy option for patients with melanoma, either as a single treatment or as a combination with MAPK inhibitors depending on ATM expression, which could serve as a novel biomarker for treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0101","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T10:10:56Z","timestamp":1691575856000},"page":"1743-1755","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction\n                    <i>In Vitro<\/i>\n                    and\n                    <i>In Vivo<\/i>"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8656-9879","authenticated-orcid":true,"given":"Lisa Marie","family":"Fr\u00f6hlich","sequence":"first","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2542-7022","authenticated-orcid":true,"given":"Heike","family":"Niessner","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3000","authenticated-orcid":true,"given":"Birgit","family":"Sauer","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8110-740X","authenticated-orcid":true,"given":"Sofie","family":"K\u00e4mereit","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-7160","authenticated-orcid":true,"given":"Eftychia","family":"Chatziioannou","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-9905","authenticated-orcid":true,"given":"Simon","family":"Riel","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-3327","authenticated-orcid":true,"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Department of Dermatology, Venereology and Allergology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-2001","authenticated-orcid":true,"given":"Birgit","family":"Schittek","sequence":"additional","affiliation":[{"name":"1Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Cluster of Excellence iFIT (EXC 2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2023090514074935900_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1011-1344(01)00199-3","article-title":"UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer","volume":"63","author":"de Gruijl","year":"2001","journal-title":"J Photochem Photobiol B"},{"key":"2023090514074935900_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov"},{"key":"2023090514074935900_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10555-013-9433-9","article-title":"Targeting MAPK pathway in melanoma therapy","volume":"32","author":"Cheng","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"2023090514074935900_bib4","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3390\/ijms21134576","article-title":"Targeted therapy in melanoma and mechanisms of resistance","volume":"21","author":"Czarnecka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023090514074935900_bib5","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023090514074935900_bib6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2023090514074935900_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat Rev Genet"},{"key":"2023090514074935900_bib8","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2023090514074935900_bib9","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.3390\/cancers13184520","article-title":"PARP inhibitors in melanoma-an expanding therapeutic option?","volume":"13","author":"Chan","year":"2021","journal-title":"Cancers"},{"key":"2023090514074935900_bib10","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/cells11091466","article-title":"Novel therapeutic approaches with DNA damage response inhibitors for melanoma treatment","volume":"11","author":"Maresca","year":"2022","journal-title":"Cells"},{"key":"2023090514074935900_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41419-020-2702-y","article-title":"Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition","volume":"11","author":"Makino","year":"2020","journal-title":"Cell Death Dis"},{"key":"2023090514074935900_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/2159-8290.CD-18-0879","article-title":"MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas","volume":"9","author":"Maertens","year":"2019","journal-title":"Cancer Discov"},{"key":"2023090514074935900_bib13","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023090514074935900_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41419-018-0952-8","article-title":"Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs","volume":"9","author":"Makino","year":"2018","journal-title":"Cell Death Dis"},{"key":"2023090514074935900_bib15","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1038\/s41467-019-10646-7","article-title":"Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors","volume":"10","author":"Bitschar","year":"2019","journal-title":"Nat Commun"},{"key":"2023090514074935900_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ebiom.2016.04.037","article-title":"A nexus consisting of Beta-catenin and Stat3 attenuates BRAF inhibitor efficacy and mediates acquired resistance to vemurafenib","volume":"8","author":"Sinnberg","year":"2016","journal-title":"EBioMedicine"},{"key":"2023090514074935900_bib17","doi-asserted-by":"crossref","first-page":"101876","DOI":"10.1016\/j.redox.2021.101876","article-title":"Corrigendum to OpenComet: an automated tool for comet assay image analysis [Redox Biol. Volume Pages 457\u2013465]","volume":"40","author":"Gyori","year":"2021","journal-title":"Redox Biol"},{"key":"2023090514074935900_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","article-title":"OpenComet: an automated tool for comet assay image analysis","volume":"2","author":"Gyori","year":"2014","journal-title":"Redox Biol"},{"key":"2023090514074935900_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1541-7786.MCR-17-0528","article-title":"YB-1 expression and phosphorylation regulate tumorigenicity and invasiveness in melanoma by influencing EMT","volume":"16","author":"Kosnopfel","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2023090514074935900_bib20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"2023090514074935900_bib21","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"key":"2023090514074935900_bib22","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2023090514074935900_bib23","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res"},{"key":"2023090514074935900_bib24","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1158\/0008-5472.CAN-21-3201","article-title":"PARP inhibitors \u2013 trapped in a toxic love affair","volume":"81","author":"Krastev","year":"2021","journal-title":"Cancer Res"},{"key":"2023090514074935900_bib25","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jid.2021.01.024","article-title":"Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach","volume":"141","author":"Kim","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023090514074935900_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","article-title":"ATM kinase: much more than a DNA damage responsive protein","volume":"39","author":"Guleria","year":"2016","journal-title":"DNA Repair"},{"key":"2023090514074935900_bib27","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023090514074935900_bib28","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"2023090514074935900_bib29","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1-and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res"},{"key":"2023090514074935900_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl Oncol"},{"key":"2023090514074935900_bib31","doi-asserted-by":"crossref","first-page":"11869","DOI":"10.1073\/pnas.1220898110","article-title":"The mTOR pathway negatively controls ATM by up-regulating miRNAs","volume":"110","author":"Shen","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023090514074935900_bib32","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","article-title":"Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"2023090514074935900_bib33","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"2023090514074935900_bib34","doi-asserted-by":"crossref","first-page":"e1003531","DOI":"10.1371\/journal.pgen.1003531","article-title":"PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation","volume":"9","author":"Rodriguez","year":"2013","journal-title":"PLoS Genet"},{"key":"2023090514074935900_bib35","first-page":"1149","article-title":"Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells","volume":"53","author":"Fratangelo","year":"2018","journal-title":"Int J Oncol"},{"key":"2023090514074935900_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","article-title":"Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage","volume":"42","author":"Karimian","year":"2016","journal-title":"DNA Repair"},{"key":"2023090514074935900_bib37","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","article-title":"Requirement for p53 and p21 to sustain G(2) arrest after DNA damage","volume":"282","author":"Bunz","year":"1998","journal-title":"Science"},{"key":"2023090514074935900_bib38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/cancers11101475","article-title":"The role of the cyclin dependent kinase inhibitor p21(cip1\/waf1) in targeting cancer: molecular mechanisms and novel therapeutics","volume":"11","author":"Al Bitar","year":"2019","journal-title":"Cancers"},{"key":"2023090514074935900_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"2023090514074935900_bib40","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"2023090514074935900_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Drean","year":"2016","journal-title":"Crit Rev Oncol Hemat"},{"key":"2023090514074935900_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers12020394","article-title":"PARP inhibitors as therapeutics: beyond modulation of PARylation","volume":"12","author":"Min","year":"2020","journal-title":"Cancers"},{"key":"2023090514074935900_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"key":"2023090514074935900_bib44","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.18632\/oncotarget.14002","article-title":"LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer","volume":"8","author":"Vakana","year":"2017","journal-title":"Oncotarget"},{"key":"2023090514074935900_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"2023090514074935900_bib46","doi-asserted-by":"crossref","article-title":"Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations [abstract]","author":"Kurnit","DOI":"10.1158\/1538-7445.AM2019-CT020"},{"key":"2023090514074935900_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/jcm8040435","article-title":"PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers","volume":"8","author":"Keung","year":"2019","journal-title":"J Clin Med"},{"key":"2023090514074935900_bib48","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.32143","article-title":"Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas","volume":"145","author":"Yi","year":"2019","journal-title":"Int J Cancer"},{"key":"2023090514074935900_bib49","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1158\/1078-0432.CCR-17-2186","article-title":"The HRD decision-which PARP inhibitor to use for whom and when","volume":"23","author":"Kohn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023090514074935900_bib50","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0101\/3356228\/crc-23-0101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1743\/3362329\/crc-23-0101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1743\/3362329\/crc-23-0101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:08:41Z","timestamp":1693908521000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/9\/1743\/728883\/PARP-Inhibitors-Effectively-Reduce-MAPK-Inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0101","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.23968297","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089882.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089900.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912577","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968291","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089885","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089891.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089897","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089903.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089891","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089906.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089900","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912580","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968297.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968294.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968291.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089906","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968294","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089897.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089894","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089882","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089894.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912577.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089903","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912580.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912583.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089888","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912583","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089885.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24089888.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6782025.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6782025.v3","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912583.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912577","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912583","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912580.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968291","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968297","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912577.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6782025.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6782025","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968294.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968297.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23912580","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968291.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23968294","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}